The development of a hepatitis C virus prophylactic vaccine strategy
<p>The success of directly-acting antivirals (DAA) has revolutionised hepatitis C virus (HCV) treatment, yet a prophylactic HCV vaccine remains an important clinical asset to achieve HCV elimination by 2030. To date, the development of a prophylactic HCV vaccine has been hindered by viral geno...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
2019
|
| Subjects: |